JFG
BBIO icon

Jefferies Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Jefferies Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$77.3K – 1417
2024
Q1 		$77.3K Buy
+2,500
New +$85K ﹤0.01% 1466

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Jefferies Financial Group's BBIO Position: Q2 2026 in Review

Jefferies Financial Group increased its BridgeBio Pharma (BBIO) stake by 87% in Q2 2026, buying an estimated $4.99M and bringing the position to 153,615 shares worth $11.4M. The position accounts for 0.08% of the portfolio, ranked #228.

Jefferies Financial Group first reported a position in BBIO in Q1 2023 and has held it in 9 quarters since. The position peaked at $15.3M in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Jefferies Financial Group held 153,615 shares of BridgeBio Pharma worth $11.4M as of Q2 2026.
  • Jefferies Financial Group bought 71,315 BridgeBio Pharma shares in Q2 2026, an estimated $4.99M.
  • BridgeBio Pharma made up 0.08% of Jefferies Financial Group's portfolio in Q2 2026, its #228 holding.
  • Jefferies Financial Group first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 9 quarters since.
  • Jefferies Financial Group's BridgeBio Pharma position peaked at $15.3M in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.